Table 3.
Comparison of clinical characteristics between the low- and high-risk groups in the development and validation cohorts.
| Development cohort (n=351) | P-Value | Validation cohort (n=150) | P-Value | |||
|---|---|---|---|---|---|---|
| Low-risk (n=224) |
High-risk (n=127) |
Low-risk (n=93) |
High-risk (n=57) |
|||
| Sex, No. (%) | 0.02 | 0.42 | ||||
| Male | 131 (58.5) | 57 (44.9) | 43 (46.2) | 31 (54.4) | ||
| Female | 93 (41.5) | 70 (55.1) | 50 (53.8) | 26 (45.6) | ||
| Onset age, mean (SD), y | 39.3 (20.3) | 54.2 (13.7) | <0.001 | 37.7 (21.3) | 55.0 (14.6) | <0.001 |
| RNS findings, No. (%) | <0.001 a | <0.001 a | ||||
| Normal | 162 (72.3) | 8 (6.3) | 73 (78.5) | 9 (15.8) | ||
| Abnormal | 62 (27.7) | 119 (93.7) | 20 (21.5) | 48 (84.2) | ||
| AChR-Ab, No. (%) | <0.001 a | <0.001 a | ||||
| Seronegative | 89 (39.7) | 0 (0.0) | 41 (44.1) | 2 (3.5) | ||
| Seropositive | 135 (60.3) | 127 (100.0) | 52 (55.9) | 55 (96.5) | ||
| Thymic status, No. (%) | <0.001 a | <0.007 a | ||||
| Normal | 163 (72.8) | 63 (49.6) | 67 (72.0) | 29 (50.9) | ||
| Thymic hyperplasia | 48 (21.4) | 23 (18.1) | 17 (18.3) | 12 (21.1) | ||
| Thymoma | 13 (5.8) | 41 (32.3) | 9 (9.7) | 16 (28.1) | ||
| Follow-up time, median (IQR), m | 23.50 [8.00, 60.00] | 12.00 [7.00, 31.00] | 0.003 b | 24.00 [10.00, 49.00] | 12.00 [6.00, 24.00] | 0.001 b |
SD, standard deviation; IQR, interquartile range; RNS, repetitive nerve stimulation; AChR-Ab, acetylcholine receptor antibody; No., number.
a
Fisher exact test.
b
Mann-Whitney U test.